• 1
    Khan N, Mukhtar H. Tea polyphenols for health promotion. Life Sci. 2007; 81: 519-533.
  • 2
    Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst. 1993; 85: 1038-1049.
  • 3
    Zhang M, Zhao X, Zhang X, Holman CD. Possible protective effect of green tea intake on risk of adult leukaemia. Br J Cancer. 2008; 98: 168-170.
  • 4
    Frankenfeld CL, Cerhan JR, Cozen W, et al. Dietary flavonoid intake and non-Hodgkin lymphoma risk. Am J Clin Nutr. 2008; 87: 1439-1445.
  • 5
    Kuo YC, Yu CL, Liu CY, et al. A population-based, case-control study of green tea consumption and leukemia risk in southwestern Taiwan. Cancer Causes Control. 2009; 20: 57-65.
  • 6
    Naganuma T, Kuriyama S, Kakizaki M, et al. Green tea consumption and hematologic malignancies in Japan: the Ohsaki study. Am J Epidemiol. 2009; 170: 730-738.
  • 7
    Yang CS. Inhibition of carcinogenesis by tea. Nature. 1997; 389: 134-135.
  • 8
    Khan N, Mukhtar H. Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett. 2008; 269: 269-280.
  • 9
    Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer. 2009; 9: 429-439.
  • 10
    Leone M, Zhai D, Sareth S, Kitada S, Reed JC, Pellecchia M. Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. Cancer Res. 2003; 63: 8118-8121.
  • 11
    Bertolini F, Fusetti L, Rabascio C, Cinieri S, Martinelli G, Pruneri G. Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma. Leukemia. 2000; 14: 1477-1482.
  • 12
    Nakazato T, Ito K, Ikeda Y, Kizaki M. Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species. Clin Cancer Res. 2005; 11: 6040-6049.
  • 13
    Shanafelt T, Lee YK, Geyer SM, et al. The green tea extract epigallocatechin induces in vitro cell death in primary human lymphoma cells through an ROS dependent mechanism [abstract]. Blood (ASH Annual Meeting Abstracts). 2006; 108: Abstract 234.
  • 14
    Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood. 2004; 104: 788-794.
  • 15
    Shanafelt TD, Lee YK, Call TG, et al. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res. 2006; 30: 707-712.
  • 16
    Chow HH, Cai Y, Hakim IA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res. 2003; 9: 3312-3319.
  • 17
    Pisters KM, Newman RA, Coldman B, et al. Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol. 2001; 19: 1830-1838.
  • 18
    Shanafelt T, Call TG, Zent CS, et al. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol. 2009; 27: 3808-3814.
  • 19
    Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 2006; 66: 1234-1240.
  • 20
    Brausi M, Rizzi F, Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol. 2008; 54: 472-473.
  • 21
    Tsao AS, Liu D, Martin J, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009; 2: 931-941.
  • 22
    Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 4990-4997.
  • 23
    Shanafelt TD, Geyer SM, Bone ND, et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol. 2008; 140: 537-546.
  • 24
    Dewald GW, Brockman SR, Paternoster SF, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol. 2003; 121: 287-295.
  • 25
    Lee MJ, Prabhu S, Meng X, Li C, Yang CS. An improved method for the determination of green and black tea polyphenols in biomatrices by high-performance liquid chromatography with coulometric array detection. Anal Biochem. 2000; 279: 164-169.
  • 26
    Call TG, Phyliky RL, Noel P, et al. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc. 1994; 69: 323-328.
  • 27
    Catovsky D, Fooks J, Richards S. Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1989; 72: 141-149.
  • 28
    Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998; 338: 1506-1514.
  • 29
    Diehl LF, Karnell LH, Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer. 1999; 86: 2684-2692.
  • 30
    Molica S, Levato D. What is changing in the natural history of chronic lymphocytic leukemia? Haematologica. 2001; 86: 8-12.
  • 31
    Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst. 1999; 91: 861-868.
  • 32
    Thomas R, Ribeiro I, Shepherd P, et al. Spontaneous clinical regression in chronic lymphocytic leukaemia. Br J Haematol. 2002; 116: 341-345.
  • 33
    Ribera JM, Vinolas N, Urbano-Ispizua A, Gallart T, Montserrat E, Rozman C. “Spontaneous” complete remissions in chronic lymphocytic leukemia: report of 3 cases and review of the literature. Blood Cells. 1987; 12: 471-483.
  • 34
    Del Giudice I, Chiaretti S, Tavolaro S, et al. Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases. Blood. 2009; 114: 638-646.
  • 35
    Bode AM, Dong Z. Epigallocatechin 3-gallate and green tea catechins: united they work, divided they fail. Cancer Prev Res (Phila). 2009; 2: 514-517.
  • 36
    Fu H, He J, Mei F, et al. Lung cancer inhibitory effect of epigallocatechin-3-gallate is dependent on its presence in a complex mixture (polyphenon E). Cancer Prev Res (Phila). 2009; 2: 531-537.
  • 37
    Yan Y, Cook J, McQuillan J, et al. Chemopreventive effect of aerosolized polyphenon E on lung tumorigenesis in A/J mice. Neoplasia. 2007; 9: 401-405.
  • 38
    Janle EM, Morre DM, Morre DJ, Zhou Q, Zhu Y. Pharmacokinetics of green tea catechins in extract and sustained-release preparations. J Diet Suppl. 2008; 5: 248-263.
  • 39
    Siddiqui IA, Adhami VM, Bharali DJ, et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 2009; 69: 1712-1716.
  • 40
    Landis-Piwowar KR, Huo C, Chen D, et al. A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. Cancer Res. 2007; 67: 4303-4310.